欧洲抗体发现市场：依产品、技术和国家划分－分析与预测（2025-2035）

欧洲抗体发现市场预计将从 2025 年的 32.3 亿美元成长到 2035 年的 101.3 亿美元，2025 年至 2035 年的复合年增长率为 12.11%。

在强大的生物医学研究生态系统、尖端工程技术以及自动化和人工智慧日益普及的推动下，欧洲抗体发现市场正快速发展。对全人源和人源化抗体的需求不断增长是一项重要的发展趋势，反映了欧洲对降低免疫抗原性、安全性和特异性的重视。噬菌体展示、基因改造动物模型和糖基化工程等平台为早期计划的严谨转化研究提供了支持，同时也促进了针对自体免疫疾病、感染疾病和肿瘤的标靶药物的开发。

同时，欧洲企业正将自动化、人工智慧驱动的建模、次世代定序和高通量筛检等技术结合，以加速抗体的选择和最佳化。对产学研合作和受託研究机构的日益依赖，正在提升专业技术的扩充性和可用性。单域抗体、抗体药物复合体和双特异性抗体等创新技术的涌现，拓展了治疗的可能性，即使面对基因和细胞疗法的竞争，也为欧洲的长期成长奠定了基础。

市场介绍

凭藉着雄厚的大学科学研究实力、现代化的医疗基础设施以及不断涌现的创新生物技术公司，欧洲的抗体研发产业正崛起为全球生物製剂生态系统的重要组成部分。欧洲汇集了许多世界一流的研究机构和製药公司，为肿瘤学、免疫学、感染疾病和罕见疾病领域的抗体研发创造了有利环境。对标靶精准药物日益增长的需求，使抗体成为优先治疗方法，并推动了全部区域对早期药物研发和平台创新的持续投资。

欧洲市场以技术创新为特征。对提高安全性、特异性和临床成功率的需求推动了全人源抗体和人源化抗体的应用。糖基化工程、基因改造动物模型和噬菌体展示是常用的药物发现平台，而自动化、次世代定序和高通量筛检则简化了抗体的鑑定和最佳化。同时，机器学习和人工智慧正被整合到药物发现流程中，以改善可开发性评估、亲和性成熟和标靶选择。

製药公司、生物技术公司、受託研究机构)和大学之间的紧密合作也是欧洲抗体发现领域的显着特征。将越来越多的发现活动外包给专业的 CRO，有助于提高规模化生产和成本效益。儘管面临高昂的研发成本和其他疗法的竞争等挑战，但发现方法的持续创新和有利的法规结构，使欧洲抗体发现市场具备了长期成长和战略重要性的优势。

市场区隔:

细分 1：依产品/服务

• 产品
• 服务

细分2：依技术

• 噬菌体展示技术
• 融合瘤技术
• 单B细胞技术
• 基因改造动物技术
• 其他的

细分3：按地区

• 欧洲

欧洲抗体发现市场的趋势、驱动因素与挑战

市场趋势

• 人工智慧和机器学习在标靶辨识、抗体设计和先导药物最适化的应用正在加速，缩短了发现的时间。
• 新一代抗体形式，如双特异性抗体、抗体药物复合体（ADC）、奈米抗体和工程化片段，正被越来越多地应用。
• 扩展我们的端到端药物发现平台，该平台整合了湿实验室筛检和计算生物学。
• 人们越来越依赖受託研究机构(CRO) 和专业服务供应商进行抗体发现和早期开发。
• 更重视功能优先和转化性检测（包括基于细胞和疾病相关的筛检模型）。

主要市场驱动因素

• 癌症、自体免疫疾病和慢性疾病领域对标靶生物製药的需求强劲且持续。
• 製药公司加大研发投入，以及大量创业投资资金涌入专门从事抗体技术的Start-Ups新创公司。
• 单细胞分析、高通量筛检、定序和微流体取得了技术进展。
• 成本和生产力压力正在推动外包和基于平台的药物发现模式的发展。
• 欧洲主要市场为生物製药和精准医疗创造了有利的法规环境。

主要挑战

• 高品质、标准化的资料集有限，无法充分训练和检验人工智慧驱动的药物发现模型。
• 先进的药物研发平台和数位基础设施需要高昂的资本和营运成本；
• 人工智慧设计的抗体和共用资料集的复杂智慧财产权所有权。
• 人工智慧驱动的药物发现结果的检验、可重复性和核准过程方面存在监管不确定性。
• 服务供应商和技术平台分散，导致供应商选择和基准测试变得困难。

产品/创新：本报告帮助您辨识欧洲抗体发现市场的高价值机会。报告重点在于药物发现平台、工程技术和治疗应用领域中由创新主导的成长。报告提供研发投资策略、技术应用和产品线优化的指南，帮助您优先推进先导化合物化合物的发现、候选药物的检验和抗体的最佳化。

成长/行销：本报告深入分析了区域市场采纳趋势、新兴市场和伙伴关係机会，旨在为企业製定策略性市场进入和商业化规划提供支援。企业可以藉此识别产品、技术、应用领域和终端用户细分市场的成长潜力。了解区域研发投入、法规结构和技术采纳率，有助于企业优化行销、授权和合作策略，从而在竞争激烈的市场环境中最大限度地提高知名度并提升投资回报率。

竞争分析：本报告提供全面的公司概况、竞争基准分析，并重点介绍策略联盟、资金筹措活动、併购以及技术应用趋势。相关人员可以清楚了解竞争对手的关注领域、研发重点和市场定位。这些洞察有助于企业识别差距并预测市场变化，从而製定差异化策略、优化市场进入策略，并在抗体发现生态系统中保持领先地位。

目录

执行摘要

第一章 市场：产业展望

• 监管状态/合规性
  • 欧洲联盟
• 定价分析
  • 副产品
  • 按地区
• 供应链分析
• 价值链分析
• 专利分析
  • 按国家/地区
  • 公司
• 市场动态
  • 趋势、驱动因素、挑战与机会：现况与未来影响评估（2024-2035年）
  • 市场趋势
  • 市场驱动因素
  • 市场挑战
  • 市场机会

第二章 区域

• 区域概况
• 欧洲
  • 区域概览
  • 市场成长驱动因素
  • 成长抑制因素
  • 透过提供
  • 透过技术
  • 按国家/地区

3. 市场－竞争标竿分析与公司概况

• 产品映射
  • 公司
  • 透过提供
  • 透过技术
• 管道分析
• 公司简介
  • Genmab A/S

第四章调查方法

This report can be delivered in 2 working days.

Introduction to Europe Antibody Discovery Market

The Europe antibody discovery market is projected to reach $10.13 billion by 2035 from $3.23 billion in 2025, growing at a CAGR of 12.11% during the forecast period 2025-2035. The market for antibody discovery in Europe is developing quickly thanks to robust biomedical research ecosystems, cutting-edge engineering technologies, and growing automation and artificial intelligence adoption. The increasing demand for totally human and humanized antibodies is a significant development that reflects Europe's emphasis on reduced immunogenicity, safety, and specificity. Phage display, transgenic animal models, and glycoengineering are examples of platforms that support translational rigor in early-stage projects while facilitating the development of targeted medicines for autoimmune, infectious, and oncology disorders.

Simultaneously, European businesses are combining automation, AI-driven modeling, next-generation sequencing, and high-throughput screening to speed up antibody selection and optimization. Scalability and availability to specialized skills are being improved by a greater dependence on academic-industry partnerships and contract research companies. By expanding therapeutic potential through innovations in single-domain antibodies, antibody-drug conjugates, and bispecific antibodies, Europe is positioned for long-term growth even in the face of competition from gene and cell therapies.

Market Introduction

The European antibody discovery industry is emerging as a vital component of the global biologics ecosystem, bolstered by a solid foundation of university research, modern healthcare infrastructure, and a growing number of innovative biotech firms. A favorable environment for antibody discovery in oncology, immunology, infectious illnesses, and uncommon disorders is created by the presence of some of the top research institutes and pharmaceutical companies in the world in Europe. Antibodies have become the preferred therapeutic modality due to the growing demand for targeted and precision therapeutics, which has led to a continuous investment in early-stage discovery and platform innovation throughout the region.

The European market is distinguished by technological innovation. The desire to increase safety, specificity, and clinical success rates is driving the adoption of both completely human and humanized antibodies. Glycoengineering, transgenic animal models, and phage display are common discovery platforms, and automation, next-generation sequencing, and high-throughput screening are simplifying antibody identification and optimization. Simultaneously, machine learning and artificial intelligence are being included into discovery workflows to improve developability evaluation, affinity maturation, and target selection.

Strong cooperation between pharmaceutical corporations, biotechnology businesses, contract research organizations, and university institutions is another feature of the antibody discovery scene in Europe. Scalability and cost-effectiveness are made possible by the growing outsourcing of discovery tasks to specialist CROs. The European antibody discovery market is positioned for long-term growth and strategic significance due to ongoing innovation in discovery methods and supporting regulatory frameworks, despite obstacles such high development costs and competition from other modalities.

Market Segmentation:

Segmentation 1: By Offering

• Product
• Services

Segmentation 2: By Technology

• Phage Display Technology
• Hybridoma Technology
• Single B-Cell Technologies
• Transgenic Animal-based Methods
• Other Technologies

Segmentation 3: By Region

• Europe

Europe Antibody discovery Market Trends, Drivers and Challenges

Market Trends

• Accelerated adoption of AI and machine learning for target identification, antibody design, and lead optimization, reducing discovery timelines.
• Growing use of next-generation antibody formats such as bispecific antibodies, antibody-drug conjugates (ADCs), nanobodies, and engineered fragments.
• Expansion of integrated, end-to-end discovery platforms combining wet-lab screening with computational biology.
• Rising reliance on CROs and specialized service providers for antibody discovery and early development.
• Increased focus on function-first and translational assays, including cell-based and disease-relevant screening models.

Key Market Drivers

• Strong and sustained demand for targeted biologics in oncology, autoimmune disorders, and chronic diseases.
• Increasing R&D investments by pharmaceutical companies and venture funding for antibody-focused biotech startups.
• Technological advancements in single-cell analysis, high-throughput screening, sequencing, and microfluidics.
• Cost and productivity pressures encouraging outsourcing and platform-based discovery models.
• Supportive regulatory outlook for biologics and precision medicine across major European markets.

Major Challenges

• Limited availability of high-quality, standardized datasets to fully train and validate AI-driven discovery models.
• High capital and operational costs associated with advanced discovery platforms and digital infrastructure.
• Complexity in intellectual property ownership for AI-designed antibodies and shared datasets.
• Regulatory ambiguity around validation, reproducibility, and approval pathways for AI-enabled discovery outputs.
• Fragmentation across service providers and technology platforms, making vendor selection and benchmarking difficult.

How can this report add value to an organization?

Product/Innovation: This report enables organizations to identify high-value opportunities in the Europe antibody discovery market, focusing on innovation-driven growth across discovery platforms, engineering technologies, and therapeutic applications. It guides R&D investment strategies, technology adoption, and pipeline optimization, allowing companies to prioritize initiatives that accelerate lead identification, candidate validation, and antibody optimization.

Growth/Marketing: The report delivers in-depth insights into regional adoption trends, emerging markets, and partnership opportunities, supporting strategic market entry and commercialization planning. It enables companies to identify growth potential across offering, technology, application, and end-user segments. By understanding regional R&D investments, regulatory frameworks, and technology adoption rates, organizations can refine marketing, licensing, and collaboration strategies, maximize visibility, and increase return on investment in a competitive landscape.

Competitive: This report provides comprehensive company profiling, competitive benchmarking, highlighting strategic collaborations, funding activities, mergers, acquisitions, and technology adoption trends. Stakeholders gain a clear understanding of competitor focus areas, R&D priorities, and market positioning. This intelligence allows organizations to identify gaps, anticipate market shifts, and formulate strategies to differentiate themselves, optimize market entry, and maintain leadership in the antibody discovery ecosystem.

Table of Contents

Executive Summary

Scope and Definition

1 Market: Industry Outlook

• 1.1 Regulatory Landscape / Compliance
  • 1.1.1 E.U.
    • 1.1.1.1 Germany
    • 1.1.1.2 France
    • 1.1.1.3 Italy
• 1.2 Pricing Analysis
  • 1.2.1 By Product
  • 1.2.2 By Region
• 1.3 Supply Chain Analysis
• 1.4 Value Chain Analysis
• 1.5 Patent Analysis
  • 1.5.1 By Country
  • 1.5.2 By Company
• 1.6 Market Dynamics
  • 1.6.1 Trends, Drivers, Challenges, and Opportunities: Current and Future Impact Assessment, 2024-2035
  • 1.6.2 Market Trends
    • 1.6.2.1 Shift toward Fully Human and Humanized Antibodies
    • 1.6.2.2 Increasing Reliance on High-Throughput Screening and Automation
    • 1.6.2.3 Growing Role of Contract Research Organizations (CROs)
  • 1.6.3 Market Drivers
    • 1.6.3.1 Advancements in Antibody Engineering for Therapeutic Applications
    • 1.6.3.2 Increasing Prevalence of Chronic Diseases
  • 1.6.4 Market Challenges
    • 1.6.4.1 Rising Shift Toward Alternative Antibody-Based Treatment Modalities
    • 1.6.4.2 High Costs Restrict Widespread Adoption of Antibody Therapies
  • 1.6.5 Market Opportunities
    • 1.6.5.1 Integration of Artificial Intelligence and Machine Learning in Antibody Discovery

2 Region

• 2.1 Regional Summary
• 2.2 Europe
  • 2.2.1 Regional Overview
  • 2.2.2 Driving Factors for Market Growth
  • 2.2.3 Factors Challenging the Market
  • 2.2.4 By Offering
  • 2.2.5 By Technology
  • 2.2.6 By Country
    • 2.2.6.1 U.K.
      • 2.2.6.1.1 By Offering
      • 2.2.6.1.2 By Technology
    • 2.2.6.2 Germany
      • 2.2.6.2.1 By Offering
      • 2.2.6.2.2 By Technology
    • 2.2.6.3 France
      • 2.2.6.3.1 By Offering
      • 2.2.6.3.2 By Technology
    • 2.2.6.4 Italy
      • 2.2.6.4.1 By Offering
      • 2.2.6.4.2 By Technology
    • 2.2.6.5 Spain
      • 2.2.6.5.1 By Offering
      • 2.2.6.5.2 By Technology
    • 2.2.6.6 Sweden
      • 2.2.6.6.1 By Offering
      • 2.2.6.6.2 By Technology
    • 2.2.6.7 Netherlands
      • 2.2.6.7.1 By Offering
      • 2.2.6.7.2 By Technology
    • 2.2.6.8 Rest-of-Europe
      • 2.2.6.8.1 By Offering
      • 2.2.6.8.2 By Technology

3 Markets - Competitive Benchmarking & Company Profiles

• 3.1 Product Mapping
  • 3.1.1 By Company
  • 3.1.2 By Offering
  • 3.1.3 By Technology
• 3.2 Pipeline Analysis
• 3.3 Company Profiles
  • 3.3.1 Genmab A/S
    • 3.3.1.1 Overview
    • 3.3.1.2 Top Products/Product Portfolio
    • 3.3.1.3 Top Competitors
    • 3.3.1.4 Target Customers
    • 3.3.1.5 Key Personal
    • 3.3.1.6 Analyst View

4 Research Methodology

• 4.1 Data Sources
  • 4.1.1 Primary Data Sources
  • 4.1.2 Secondary Data Sources
  • 4.1.3 Data Triangulation
• 4.2 Market Estimation and Forecast

List of Figures

• Figure 1: Europe Antibody Discovery Market (by Scenario), $Billion, 2024, 2030, and 2035
• Figure 2: Antibody Discovery Market (by Region), $Billion, 2024 and 2035
• Figure 3: Europe Antibody Discovery Market (by Offering), $Billion, 2024, 2030, and 2035
• Figure 4: Europe Antibody Discovery Market (by Technology), $Billion, 2024, 2030, and 2035
• Figure 5: Antibody Discovery Market, Value Chain Analysis
• Figure 6: Antibody Discovery Market, Patent Analysis (by Country), January 2022- August 2025
• Figure 7: Antibody Discovery Market, Patent Analysis (by Company), January 2022- August 2025
• Figure 8: Europe Antibody Discovery Market, $Billion, 2024-2035
• Figure 9: U.K. Antibody Discovery Market, $Billion, 2024-2035
• Figure 10: Germany Antibody Discovery Market, $Billion, 2024-2035
• Figure 11: France Antibody Discovery Market, $Billion, 2024-2035
• Figure 12: Italy Antibody Discovery Market, $Billion, 2024-2035
• Figure 13: Spain Antibody Discovery Market, $Billion, 2024-2035
• Figure 14: Sweden Antibody Discovery Market, $Billion, 2024-2035
• Figure 15: nds Antibody Discovery Market, $Billion, 2024-2035
• Figure 16: Rest-of-Europe Antibody Discovery Market, $Billion, 2024-2035
• Figure 17: Antibody Discovery Market, Product Mapping (by Company)
• Figure 18: Data Triangulation
• Figure 19: Top-Down and Bottom-Up Approach
• Figure 20: Assumptions and Limitations

List of Tables

• Table 1: Market Snapshot
• Table 2: Pricing Analysis (by Region)
• Table 3: Antibody Discovery Market (by Region), $Billion, 2024-2035
• Table 4: Europe Antibody Discovery Market (by Offering), $Billion, 2024-2035
• Table 5: Europe Antibody Discovery Market (by Technology), $Billion, 2024-2035
• Table 6: U.K. Antibody Discovery Market (by Offering), $Billion, 2024-2035
• Table 7: U.K. Antibody Discovery Market (by Technology), $Billion, 2024-2035
• Table 8: Germany Antibody Discovery Market (by Offering), $Billion, 2024-2035
• Table 9: Germany Antibody Discovery Market (by Technology), $Billion, 2024-2035
• Table 10: France Antibody Discovery Market (by Offering), $Billion, 2024-2035
• Table 11: France Antibody Discovery Market (by Technology), $Billion, 2024-2035
• Table 12: Italy Antibody Discovery Market (by Offering), $Billion, 2024-2035
• Table 13: Italy Antibody Discovery Market (by Technology), $Billion, 2024-2035
• Table 14: Spain Antibody Discovery Market (by Offering), $Billion, 2024-2035
• Table 15: Spain Antibody Discovery Market (by Technology), $Billion, 2024-2035
• Table 16: Sweden Antibody Discovery Market (by Offering), $Billion, 2024-2035
• Table 17: Sweden Antibody Discovery Market (by Technology), $Billion, 2024-2035
• Table 18: Netherlands Antibody Discovery Market (by Offering), $Billion, 2024-2035
• Table 19: Netherlands Antibody Discovery Market (by Technology), $Billion, 2024-2035
• Table 20: Rest-of-Europe Antibody Discovery Market (by Offering), $Billion, 2024-2035
• Table 21: Rest-of-Europe Antibody Discovery Market (by Technology), $Billion, 2024-2035
• Table 22: Antibody Discovery Market, Product Mapping (by Offering)
• Table 23: Antibody Discovery Market
• Table 24: Pipeline Analysis